Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;10(2):171-178.
doi: 10.21037/jgo.2018.12.12.

Local excision for patients with stage I anal canal squamous cell carcinoma can be curative

Sakti Chakrabarti  1 , Zhaohui Jin  1 , Brandon M Huffman  1 , Siddhartha Yadav  1 , Rondell P Graham  2 , Dora M Lam-Himlin  3 , Amy L Lightner  4 , Christopher L Hallemeier  5 , Amit Mahipal  1
Affiliations

Local excision for patients with stage I anal canal squamous cell carcinoma can be curative

Sakti Chakrabarti et al. J Gastrointest Oncol. 2019 Apr.

Abstract

Background: Definitive concurrent chemoradiation is the current standard of care for all stage I anal canal squamous cell carcinoma. Local excision as primary treatment for selected stage I lesions has been reported in the literature but is not currently recommended by major guidelines. We herein compared the oncologic outcomes of patients with stage I anal canal squamous cell carcinoma treated with local excision alone versus chemoradiation to determine if there are any significant differences in outcomes including disease free survival, overall survival (OS) and local failure rate.

Methods: A retrospective review of all patients treated for stage I anal canal squamous cell carcinoma between 1990 and 2016 was conducted. Data collected included baseline demographics, staging studies, pathology, treatment received, relapse pattern and survival.

Results: A total of 57 patients were treated for stage I anal canal squamous cell carcinoma between 1990 and 2016; 13 were treated with local excision alone and 44 were treated with chemoradiation therapy. Baseline characteristics in both cohorts of patients were comparable. Median follow-up duration of the local excision and the chemoradiation cohorts were 106 and 70 months, respectively. Of the 13 patients in local excision cohort, two patients had disease recurrence, at 21 and 97 months from the diagnosis. Both patients were long term survivors with salvage treatment. In chemoradiation cohort, 1 out of 44 patients had a local recurrence at 1 year who underwent curative resection. Five-year progression free survival (PFS) of subjects in local excision cohort and chemoradiation cohort were 91% and 83%, respectively (P=0.57).

Conclusions: Local excision as primary treatment may be safe and effective for a selected group of stage I anal canal squamous cell carcinoma patients.

Keywords: Anal canal; chemoradiation; local excision; squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Kaplan-Meier curve of progression free survival of stage I anal squamous cell carcinoma patients treated with local excision alone (LE cohort, n=13) versus patients treated with definitive chemoradiation (CRT cohort, n=44).
Figure 2
Figure 2
Kaplan-Meier curve of overall survival of stage I anal squamous cell carcinoma patients treated with local excision alone (LE cohort, n=13) versus patients treated with definitive chemoradiation (CRT cohort, n=44).
See this image and copyright information in PMC

References

    1. Surveillance, Epidemiology, and End Results Program. Stat fact sheets: anal cancer. Available online: http://seer.cancer.gov/statfacts/html/anus.html, accessed on August 1, 2018.
    1. van der Zee RP, Richel O, de Vries HJ, et al. The increasing incidence of anal cancer: can it be explained by trends in risk groups? Neth J Med 2013;71:401-11. - PubMed
    1. Benson AB III VA, et al. NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma, Version 1. 2018.
    1. Glynne-Jones R, Nilsson PJ, Aschele C, et al. Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25:iii10-20. 10.1093/annonc/mdu159 - DOI - PubMed
    1. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348:1049-54. 10.1016/S0140-6736(96)03409-5 - DOI - PubMed